These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Inclusions fixing thioflavin T in plasmacytes of IgG lambda myeloma with amylosis]. Canioni D; Kermarec J Arch Anat Cytol Pathol; 1982; 30(5-6):279-83. PubMed ID: 6188417 [No Abstract] [Full Text] [Related]
6. Congo red-positive cardiac kappa-AL amyloidosis in plasmacytoma -- case report and review of the literature. Tzankov A; Pölzl G; Mairinger T Acta Med Austriaca; 2003; 30(1):29-32. PubMed ID: 12558564 [TBL] [Abstract][Full Text] [Related]
7. Demonstration of changes in plasma cell subsets in multiple myeloma. Ayliffe MJ; Davies FE; de Castro D; Morgan GJ Haematologica; 2007 Aug; 92(8):1135-8. PubMed ID: 17650446 [TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies]. Gödecke V; Schmidt JJ; Bräsen JH; Koenecke C; Haller H Internist (Berl); 2019 Jan; 60(1):10-22. PubMed ID: 30635666 [TBL] [Abstract][Full Text] [Related]
13. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions. Milani P; Palladini G; Merlini G Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897 [TBL] [Abstract][Full Text] [Related]
14. Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Siragusa S; Morice W; Gertz MA; Kyle RA; Greipp PR; Lust JA; Witzig TE; Lacy MQ; Zeldenrust SR; Rajkumar SV; Russell SJ; Hayman SR; Buadi F; Kumar SK; Dingli D; Dispenzieri A Ann Hematol; 2011 Jan; 90(1):101-6. PubMed ID: 20645101 [TBL] [Abstract][Full Text] [Related]
16. [Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma]. Schleiffenbaum BE Praxis (Bern 1994); 2012 Nov; 101(24):1521-9; quiz 1530-1. PubMed ID: 23184544 [No Abstract] [Full Text] [Related]
17. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Buxbaum J; Gallo G Hematol Oncol Clin North Am; 1999 Dec; 13(6):1235-48. PubMed ID: 10626147 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137 [TBL] [Abstract][Full Text] [Related]
19. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348 [TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Gertz MA Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]